The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Deep-learning analysis of H&E images to define three immune phenotypes to reveal loss-of-target in excluded immune cells as a novel resistance mechanism of immune checkpoint inhibitor in non-small cell lung cancer.
 
Sehhoon Park
Stock and Other Ownership Interests - Lunit
 
Chan-Young Ock
Employment - Lunit
Leadership - Lunit
Stock and Other Ownership Interests - Lunit; medpacto
Consulting or Advisory Role - medpacto; Y-Biologics
 
Minje Jang
Employment - Lunit
 
Jiwon Shin
Stock and Other Ownership Interests - Lunit
 
Sarah Lee
Employment - Lunit
 
Kyunghyun Paeng
Employment - Lunit
Leadership - Lunit
Stock and Other Ownership Interests - Lunit
 
Jonghanne Park
Employment - Novartis (I)
 
Young Kwang Chae
Consulting or Advisory Role - AstraZeneca; Biodesix; Boehringer Ingelheim; Counsyl; Foundation Medicine; Guardant Health; Hanmi; Immuneoncia; Lilly; Roche/Genentech; Takeda; Tempus
Speakers' Bureau - AstraZeneca; Genentech/Roche; Lilly; Merck
Research Funding - Abbvie; Biodesix; Bristol-Myers Squibb; Freenome; Lexent Bio
Travel, Accommodations, Expenses - Hanmi
 
Yoon La Choi
No Relationships to Disclose
 
Tony S. K. Mok
Employment - The Chinese University of Hong Kong
Leadership - AstraZeneca; Hutchison MediPharma; Sanomics Limited
Stock and Other Ownership Interests - Hutchison MediPharma; Sanomics Limited
Honoraria - ACEA Biosciences; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Fishawack Facilitate; Hutchison MediPharma; Ignyta; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech; SFJ Pharmaceuticals Group; Takeda; Vertex
Consulting or Advisory Role - ACEA Biosciences; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Cirina; Clovis Oncology; geneDecode; Hutchison MediPharma; Ignyta; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Oncogenex; Pfizer; Roche/Genentech; SFJ Pharmaceuticals Group; Vertex
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); SFJ Pharmaceuticals Group (Inst); Xcovery (Inst)
 
Se-Hoon Lee
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Novartis; Roche
Research Funding - Merck
Travel, Accommodations, Expenses - Novartis